

CONFERENCE PROGRAM

The Ninth International Conference on
HUMAN ANTIBODIES & HYBRIDOMAS

16-18 September 2002
University Hospital, Berne, Switzerland

Sponsored by the International Journal **HUMAN ANTIBODIES**
 In Association with **The Rajko Medenica Research Foundation** and **Shantha Biotechnics PVT Ltd.**

Programme Chairman **Mark Glassy** (*Professor, RMRF, San Diego, USA*)

Scientific Advisory Panel

Keith James (*University of Edinburgh, UK*)
Zdenka L. Jonak (*GlaxoSmithKline, USA*)
Yehuda Shoefeld (*Tel Aviv University, Israel*)
Albert Lo Baglio (*University of Alabama, USA*)
Greg Winter (*Medical Research Council, Cambridge, UK*)
Hakan Mellstedt (*Karolinska Institute, Sweden*)
Kathy Potter (*Southampton University, UK*)
Jim Larrick (*Plenar Biotechnology Inc., USA*)

Local Organiser:
Alois Lang (*BERNA BIOTECH, Switzerland*)
Keynote Speakers:
J Donald Capra (*DMRE Oklahoma, USA*)
Yehuda Shoefeld (*Tel-Aviv University, Israel*)
James Larrick (*Plenar Biotechnology, San Diego, USA*)
Hermann Waldmann (*University of Oxford, UK*)
Alois Lang (*Berne Biotech, Berne, Switzerland*)

CONFERENCE PROGRAM

THE HAH 2002 CONFERENCE FACILITY AND THE ORGANIZERS WOULD LIKE TO ACKNOWLEDGE THE SUPPORT OF THE FOLLOWING SPONSORS:



HAH 2002 Conference Secretariat, MEETINGS MANAGEMENT
 The Barn, Rake Meadow, Station Lane, Milford, Surrey GU8 5AD, United Kingdom
 Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
 Email: csumner@meetingsmgmt.u-nci.com Website: www.meetingsmanagement.com

CONFERENCE PROGRAM

MONDAY 16TH SEPTEMBER 2002

- 07.30 - 08.50** Registration
- 08.50 - 09.00** **Welcome to Berne**
Dr Alois Lang (Bama Biotech, Berne, Switzerland)
Opening Remarks
Professor Mark Glassy (The Rajko Medenica Research Foundation)
- 09.00 - 09.30** **Opening Keynote Lecture:**
Receptor revision is a common mechanism of antibody diversification in human B cells
J.Donald Capra and Patrick Wilson (DMRF, Oklahoma, USA)
- SESSION 1 CANCER**
- Moderators:** Zdenka L. Jonak (GlaxoSmithKline, USA) & Mark C. Glassy (RMRF, San Diego, USA)
- 09.30 - 09.50** **PAM-1, a human monoclonal IgM antibody useful for diagnosis and therapy of precancerous and cancerous epithelial lesions**
H.P. Vollmers, S. Brandlein, F. Hensel, I. Beyer, M. Eck, B. Schmausser, H.K. Müller-Hermelink, (University of Würzburg, Germany)
- 09.50 - 10.10** **Multiple strategies for targeting prostate cancer with human antibodies**
N. Lonberg (Medarex, Mipitas, USA)
- 10.10 - 10.30** **New human monoclonal IgM antibodies from cancer patients with apoptotic activity**
S. Brandlein, J. Lorenz, F. Hensel, M. Eck, B. Schmausser, J. Müller, H.K. Müller-Hermelink, H.P. Vollmers (University of Würzburg, Germany)
- 10.30 - 11.00** Coffee and Posters
- 11.00 - 11.20** **Immunoglobulin repertoire analysis reveals a potential tumor-antigen binding capacity of B lymphocytes infiltrating human breast carcinomas**
B. Kotlan, P. Simsa, M.K. Tur, R. Finner, R. Fischer, S. Barth (National Medical Center/NIH, Budapest, Hungary)
- 11.20 - 11.40** **Pharmacokinetic analysis of an improved humanized monoclonal antibody designed for radioimmunotherapy (RIT)**
A.Fonero, M.B. Khazaeli, R. Meredith, M. Carpenter, J. Schlom, A. LoBuglio (University of Alabama at Birmingham, USA)
- 11.40 - 12.00** **Therapeutic activity of rituximab, a chimeric anti-CD20 monoclonal antibody, and FcγRIIIa gene polymorphism**
H. Watier, G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat (Centre Hospitalier Universitaire Tours, France)
- 12.00 - 12.20** **VN-18 and FibMab: Novel antibodies and antigens specific to tumor endothelial cells**
T. Logtenberg, J. de Kruijff, M. Geubbink, H. deBoer (Cruceff, Leiden, The Netherlands)
- 12.20 - 12.50** **In vivo treatment with SB-408075 shows evidence of antibody-toxin delivery to xenografts**
Z.L. Jonak, J.D. Winkler, Y.-J. Chen, F.L. McCabe, S.H. Trull, E. Caulder, L.M. Inlow-Porter, L. Elefante, M. Mattern, A.W. Tolcher, J. De Bono, R.K. Johnson (GlaxoSmithKline Pharmaceuticals, King of Prussia, USA)
- 12.50 - 13.45** Lunch and Posters

CONFERENCE PROGRAM

SESSION 2 AUTOIMMUNITY

- Moderators:** Y. Shoenfeld (Sheba Medical Center, Tel Aviv University, Israel)
& K. Potter (University of Southampton, UK)
- 13.45 - 14.15 Keynote Lecture:**
The infectious origin of APS. Molecular mimicry between microbial pathogens and B2-GPI: The induction of experimental APS
Y. Shoenfeld (Sheba Medical Center, Tel Aviv University, Israel)
- 14.15 - 14.35 Production of human monoclonal antibodies to desmoglein 3 from Pemphigus vulgaris patient**
K.C. Bhol, A.R. Ahmed (Harvard School of Dental Medicine, Boston, USA)
- 14.35 - 14.55 The mosaic of autoimmunity: The role of environmental factors in autoimmune diseases**
Yehuda Shoenfeld (Sheba Medical Center, Tel Aviv University, Israel)
- 14.55 - 15.15 Similar patterns of B cell perturbation are found in the peripheral blood from patients with systemic lupus erythematosus (SLE) and infectious mononucleosis (IM)**
I. Mockridge, A. Rahman, S. Buchan, T. Hamblin, D.A. Iserberg, F.K. Stevenson, K.N. Potter (Tenovus Laboratory, University of Southampton, UK)
- 15.15 - 15.45 Tea and Posters**
- 15.45 - 16.05 Search for a monoclonal antibody mimicking naturally occurring anti-C3/C3b antibodies that regulate complement amplification**
H.U. Lutz, M. Schlumberger, P.J. Spath, E. Jelezarova, A.B. Lang (ETH Zurich/ZLB Bioplasma Ltd/BernaBiotech, Switzerland)
- 16.05 - 16.25 Comparability testing of a recombinant human anti-Rh D antibody derived from two different cell lines using biophysical and biochemical parameters: relevance for scale up manufacturing**
H.-J. Krieg, S. Schurch, J. Schaller, S. Dejardin, A. Tu, S. Miescher, P.-A. Girod, N. Mermod, H. Amstutz (Inselspital, Berne, Switzerland)
- 16.25 - 16.45 Anti-dsDNA anti-idiotypic activity as the main mechanism of IVIG effect in SLE**
L. Rauova, B. Gilburd, M. Blank, I. Goldberg, J. Kopolovic, M. Ehrenfeld, J. Rovensky, Y. Shoenfeld (Sheba Medical Center, Tel Aviv University, Israel)
- 16.45 - 17.05 Functional properties of anti-D monoclonal antibodies: role of host cell expression system and in vitro correlation between ADCC and IL2 release from Jurkat CD16**
C. de Remouf, R. Belard, C. Gaucher, A. Glacet, D. Bourel (LFB, Lille Cedex, France)
- 17.05 - 17.25 In vitro functional assessment of a recombinant anti-Rh D antibody: relevance to clinical performance**
H. Amstutz, S. Dejardin, T. Hf, M. Spycher, A. Hofmann, S. Nahrgang, B. Stadler, S. Miescher, P. Lerch (Inselspital, Berne, Switzerland)
- 17.25 - 18.05 Keynote Lecture:**
If we can make any antibody we want then how come we don't have it?
James Larick (Planet Biotechnology, San Diego, USA)
- Evening Welcome Reception (Time to be confirmed)**

CONFERENCE PROGRAM

TUESDAY 17TH SEPTEMBER 2002

08.30 - 09.00 Keynote Lecture:
Stealth antibodies
Hermann Waldmann (University of Oxford, UK)

Moderator: Keith James (Edinburgh)

SESSION 3 EMERGING TECHNOLOGIES

Moderator: Keith James (Edinburgh)

09.00 - 09.20 Selection and engineering of antibodies for human therapy
D. Athwal (Celltech Chiroscience, Slough, UK)

09.20 - 09.40 The n-CoDeR™ antibody libraries: concept and applications
E. Soderlind (Bioinvent Therapeutics AB, Lund, Sweden)

09.40 - 10.00 Virus-like particles: a versatile tool for therapeutic vaccination
M. Bachmann (Cytos Biotechnology AG, Zurich-Schlieren, Switzerland)

10.00 - 10.20 Genetic immunization: a rapid way of developing high quality diagnostic or therapeutic antibodies against native proteins
J. Thompson (GENOVAC AG, Freiburg, Germany)

10.20 - 10.40 Targetting mucosal sites by polymeric immunoglobulin receptor-directed peptides
Kendra D. White, J. Donald Capra (OMRF, Oklahoma, USA)

10.40 - 11.00 Coffee and Posters

SESSION 4 MOLECULAR BIOLOGY (I)

Moderators: O.R. Burrone (ICGEB, Trieste, Italy) & R. Burioni (University of Ancona, Italy)

11.00 - 11.30 Tumor rejection in anti-idiotypic DNA vaccination is antibody-mediated
M.C. Gaspare, F. Benvenuti, O.R. Burrone (ICGEB, Trieste, Italy)

11.30 - 12.00 Engineering low affinity IgM antibodies into high affinity, fully human IgG molecules
Y. Tang, J. Xu, A.P. Vasserot, P.C. Brooks, J.D. Watkins (Applied Molecular Evolution, San Diego, USA)

12.00 - 12.30 Human membrane immunoglobulins are stabilized by inter-chain disulfide bonds within the extracellular membrane-proximal domain
M. Bestagno, L. Vangelista, P.M. Saenz, S. Mukherjee, J. Sepulveda, O.R. Burrone (International Centre for Genetic Engineering and Biotechnology, Trieste, Italy)

12.30 - 13.00 Generating human monoclonal antibodies from human cells engrafted into SCID mice
L. Jiang, R. Sabbe, R. Sawada-Hirai, F. Wang, P. Morrow, W. Scholz (Xenex Biosciences, San Diego, USA)

13.00 - 14.00 Lunch and Posters

SESSION 5 MOLECULAR BIOLOGY (II)

Moderators: O.R. Burrone (ICGEB, Trieste, Italy) & R. Burioni (University of Ancona, Italy)

14.00 - 14.20 Deimmunised immunotoxins for multiple targets
F. Carr (Biovation Ltd, Aberdeen, UK)

14.20 - 14.40 From EST to IHC - human antibodies for target validation and drug development
H. Watzka (MorphoSys AG, Martinsried, Germany)

14.40 - 15.00 Selecting and optimizing therapeutic antibody leads
C.P. Shorrock, L. Jermutus (Cambridge Antibody Technology, UK)

15.00 - 15.20 Troybodies™, a novel approach to cancer vaccines
O.H. Brekke, I. Sandlie, B. Bogen (Affitech AS, Oslo, Norway)

15.20 - 15.40 Affinity maturation of human Fab antibodies by yeast display
S.E. Hufton (Dyax SA, Belgium)

15.40 - 16.20 Coffee Break (Extended for Posters)

CONFERENCE PROGRAM

SESSION 6 POSTER SESSION

SESSION 7 MOLECULAR BIOLOGY (III)

Moderators: To be confirmed

- 16.20 - 16.40 Cloning and expression of a non-small cell lung cancer specific RM2 scfv in *Pichia pastoris***
P. Watchmaker, M. Rani, K. Kota, S. Chakrabarti, S. Mukerjee
(Shantha Biotechnics PVT Ltd, Hyderabad, India)
- 16.40 - 17.00 Human recombinant autoantibodies specific for the La (SS-B) autoantigen from patient derived phage display combinatorial antibody libraries**
J.M.H. Raats, W.F. Roeffen, A.J.C.M. van Sluisveld, S. Litjens, I. Bulduk, G. Mans, F.H.J. Van den Hoogen, G.J.M. Puijn, W.J. van Venrooij (University of Nijmegen, The Netherlands)
- 17.00 - 17.20 Production and characterization of monoclonal antibodies produced in the human cell line PER.C6**
D. Jones, N. Kroos, R. Anema, N. van Dijk, H. Kapteyn, R. Zwijsen, T. Logtenberg, A. Bout
(Crucell, Leiden, The Netherlands)
- 17.20 - 17.40 Biological activity of human 'conditional' anti-FcεR1α-chain antibodies is defined by their light chain**
M.Fux, T. Bobrzynski, M. Vogel, J. Pachlopnik, M. Horn, B.M. Stadler, S.M. Miescher
(Inselspital, Berne, Switzerland)
- 17.40 - 18.00 Human miniantibodies against orthopoxviruses**
A.A. Ilychev et al. (VECTOR, Novosibirsk, Russia)
- 18.00 - 18.20 Using XenoMouse® mice for generating optimal human antibodies for therapeutic leads**
L.L. Green (Abgenix Inc., Fremont, California, USA)
- Evening: Conference Dinner (Time to be confirmed)

WEDNESDAY 18TH SEPTEMBER 2002

SESSION 8 INFECTIOUS DISEASES

- Moderator: Alois Lang (Berna Biotech Ltd, Berne, Switzerland)
- 09.00 - 09.30 Keynote Lecture:**
Status of human monoclonal antibody therapy against gram-negative pathogens
A. Lang (BernaBiotech, Berne, Switzerland)
- 09.30 - 10.00 Molecular dissection of the anti-HCV humoral response by phage display repertoire cloning**
R. Burioni (University of Ancona, Italy)
- 10.00 - 10.30 Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 mediate cross-clade neutralization of HIV-1 primary isolates**
M.K. Gorny, C. Williams, B. Volsky, K. Revesz, S. Cohen, V. Polonis, W.J. Honnen, C. Krachmarov, A. Pintar, S. Zolla-Pazner (New York University School of Medicine, USA)
- 10.30 - 11.00 Coffee and Posters**
- 11.00 - 11.20 Aurexis™, a humanized monoclonal antibody protective against *S. aureus* infection**
J.T. Hutchins, D. Bryant, P. Domanski, L. Donald, A. Hall, P. Patel, B. Prater, J. Robbins, P. Syribey, J. Vernachio, J. Wang, L. Zhang, J.M. Patti (Inhibitor Inc., Alpharetta, Georgia, USA)
- 11.20 - 11.40 Generation of fully human monoclonal antibodies specific to bacterial and fungal pathogens in a human/mouse radiation chimera: the Trimera system**
R. Eren, S. Dagan et al. (XTL Biopharmaceuticals Ltd, Rehovot, Israel)
- 11.40 - 12.00 Human T lymphotropic virus type 1 (HTLV-1) autoantibodies and type 1 diabetes mellitus in Jamaicans**
M. Fisher Smikle (University of the West Indies, Kingston, Jamaica)
- 12.00 - 12.20 Clinical evaluation (Phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties**
R. Eren, S. Dagan et al. (XTL Biopharmaceuticals Ltd, Rehovot, Israel)
- 12.20 - 12.30 Closing remarks and invitation to attend HAH 2003 in Japan**
Prof M.C. Glassy (HAH 2002 Conference Chairman)

HAH 2002 Conference Secretariat, MEETINGS MANAGEMENT
The Barn, Rake Meadow, Station Lane, Milford, Surrey GU8 5AD, United Kingdom
Conference Manager Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
Email: csumner@meetingsmgmt.u-net.com Website: www.meetingsmanagement.com

POSTER PROGRAM

POSTER 1

Architectural features of human IgG that modulate its catabolic half-life in the rat
J. Lund et al. (University of Birmingham, UK)

POSTER 2

Synthesis of homogeneous neoglycoforms of IgG-Fc molecules and their functional properties
M. Levens et al. (University of Birmingham, UK)

POSTER 3

Selective production of monoclonal antibodies based on a B cell targeting technique
M. Tomita et al. (Me University, Tsu, Japan)

POSTER 4

Production and characterization of specific monoclonal antibodies of the human thyroid stimulating hormone
C. Acosta Bas et al. (Centro de Inmunosayo, Havana, Cuba)

POSTER 5

Monoclonal antibody against free β -subunit of human chorionic gonadotrophin
C. Acosta Bas et al. (Centro de Inmunosayo, Havana, Cuba)

POSTER 6

Monoclonal antibodies against hepatitis B S antigen: production, characterization, and use for diagnosis
C. Acosta Bas et al. (Centro de Inmunosayo, Havana, Cuba)

POSTER 7

Obtainment, production and characterization of specific monoclonal antibody of the human trypsin
C. Acosta Bas et al. (Centro de Inmunosayo, Havana, Cuba)

POSTER 8

Human miniantibodies against Ebola virus
N. Tikunova et al. (VECTOR, Novosibirsk, Russia)

POSTER 9

Generalization of a new method to reduce immunogenicity of chimeric monoclonal antibodies
C. Mateo et al. (Molecular Immunology Center, Havana, Cuba)

POSTER 10

Detection of *Schistosoma haematobium* antigens in serum and urinary tract tissue of infected hamsters using specific monoclonal antibody
F. Saleh et al. (Theodor Bilhaz Research Institute, Giza, Egypt)

POSTER 11

Assessment of monoclonal antibodies for the diagnosis of *Schistosoma haematobium* infection
F. Saleh et al. (Theodor Bilhaz Research Institute, Giza, Egypt)

POSTER 12

TNF related apoptosis inducing ligand (TRAIL) receptor antibody agonists
C.J. Gaskins, D.A. Kroe, M.S. Nasoff (Genomics Institute of the Novartis Research Foundation, San Diego, USA)

POSTER 13

Production of various human monoclonal antibodies for medical, biological, and agricultural research
H. Kawahara et al. (Kaiyushu National College of Technology, Japan)

POSTER 14

Human single chain Fv antibody specific to human monocyte chemoattractant protein-1 (MCP-1) with the inhibitory activity on the monocyte chemotaxis
K. Sugimura et al. (Kagoshima University, Japan)

POSTER 15

Human single chain Fv (scFv) antibody specific to human IL-6 with the inhibitory activity to IL-6 signalling
K. Sugimura et al. (Kagoshima University, Japan)

POSTER 16

Human Fc ϵ R1 α -specific human single chain Fv (scFv) antibody with the inhibitory activity on the histamine release assay
K. Sugimura et al. (Kagoshima University, Japan)

POSTER 17

Development of novel antigen binders based on dimerisation of VH domains
J. Sepulveda, H. Jin, O.R. Barone (IGGER, Trieste, Italy)

POSTER 18

Recombinant antibodies in cancer treatment
L. Roque Navarro (Center of Molecular Immunology, Havana, Cuba)

POSTER 19

Classification of Rift valley fever virus strains using monoclonal antibodies
M. N. Niang (Institute Pasteur de Dakar, Senegal)

POSTER 20

Immunocytigraphy of experimental tumor models using ^{99m}Tc labelled monoclonal antibodies
A. Meenakshi (Cancer Institute, Adyar, Chennai, India)

POSTER 21

In vivo diagnostic and therapeutic applications of Mab C1BCHSH3 generated to the human epidermal growth factor receptor
Y. Ganesh, A. Meenakshi et al. (Cancer Institute, Adyar, Chennai, India)

POSTER 22

Intracellular immunization with different anti-HIV-1 human antibodies
E. Moreau, C. Desgranges (Hopital St Louis, Paris, France)

POSTER 23

Do B-cell lymphomas arising in patients with type II cryoglobulinemia sustain the production of the cryoprecipitable IgM?
V. De Re, S. De Vita, D. Gasparotto et al. (CRO, Aviano, Italy)

POSTER 24

The analysis of immunoglobulin variable regions of monoclonal B-Cell expansions in Sjogren's Syndrome reveals similarities with HCV-associated lymphoproliferations of Type II cryoglobulinemia
D. Gasparotto, V. De Re et al. (CRO, Aviano, Italy)

POSTER 25

Efficient selection of high affinity phage antibodies against haptens using cleavable biotin-labeled haptenic derivative
N. Kobayashi, T. Karibe, J. Goto (Tohoku University, Sendai, Japan)

POSTER 26

Identification and validation of novel targets associated with metastasis using chromophore-assisted laser inactivation (CALI)
C. Unger, K. Jensen (Merck Pharmaceuticals AG, Munich, Germany)

POSTER 27

Preparation of the mouse and human chimeric antibodies to hypervariable region 1 (HVR1) of hepatitis C virus
C. Li, J.-P. Alain (National Blood Service, Cambridge, UK)

POSTER 28

Tumour detection from hybridoma produced c-myc antibody
V. Mehrotra, V.L. Lahiri (IIMS, Dehradun, India)

POSTER 29

High efficiency creation of human monoclonal antibody-producing hybridomas
S.K. Dossain, J.S. Stevens, R.A. Goldsby, R.A. Weinberg (The Whitehead Institute, Cambridge, Massachusetts, USA)